FDA Recommended Ersodetug Pre-BLA Meeting
Regulators advised Rezolute to discuss a potential drug application after reviewing new data on the insulin-regulating therapy.
Updated on Oct. 5, 2026 in Diabetes
Live Poll
Do you trust positive regulatory updates from biotech firms as a signal for long-term stock value?
The FDA has recommended that Rezolute request a Type B pre-BLA meeting to discuss the path forward for Ersodetug, a treatment targeting insulin-related conditions. This recommendation follows an additional analysis of glucose-monitoring data, signaling a potential step toward a future Biologics License Application.
Why it matters
This regulatory update follows a review of additional clinical analysis that may suggest potential benefits for the treatment, despite previous setbacks in a separate Phase 3 study. The shift allows Rezolute to focus on the Ersodetug program by reallocating resources from other clinical projects.
The FDA recommendation follows an evaluation of new glucose-monitoring data, which occurred after the sunRIZE Phase 3 trial failed to meet its primary and key secondary endpoints. The extent of the clinical benefit remains under investigation.
The players
FDA
The federal agency responsible for overseeing the safety, efficacy, and security of human drugs and biological products in the United States.
Rezolute
A biopharmaceutical company focused on developing therapies for metabolic and insulin-related diseases.
The details
Ersodetug is an experimental therapy designed to address issues with insulin regulation. The FDA recommendation to move toward a pre-BLA meeting indicates that the agency is willing to evaluate supplemental data beyond what was captured in the initial failed sunRIZE study. Rezolute has recently prioritized this program by pausing its RZ402 initiative for diabetic macular edema to consolidate institutional resources.
Timeline
October 5, 2026: Rezolute received the official FDA pre-BLA meeting recommendation.
Q4 2026: Topline results for the upLIFT Phase 3 trial are expected to be released.
Health Landscape
The FDA Type B pre-BLA meeting protocols provide a standardized framework for the agency to offer guidance to drug developers before they submit a formal biologics license application. This engagement follows established regulatory practices for assessing candidates that show potential despite previous trial outcomes.
This development is a regulatory update and does not impact current treatment protocols or medication availability for patients. Individuals interested in how these types of clinical developments influence future care should have a conversation with their physician.
The takeaway
Regulatory guidance meetings are a formal part of the drug development lifecycle that help clarify if a candidate has a viable path forward. Patients should focus on current evidence-based treatments and discuss any questions about future therapeutic options with their primary care provider.
What happens next
Topline results for the upLIFT Phase 3 trial are expected to be released in the fourth quarter of 2026.
Further reading
For more information on the management of glucose levels and experimental therapies, visit our Diabetes section.
Live Poll
Do you trust positive regulatory updates from biotech firms as a signal for long-term stock value?
